Evotec tumbled on Wednesday after the German biotech firm warned on profits.
Evotec AG
07 August 2024 13:17:13
Source: Sharecast
In a press release late on Tuesday, Evotec cut its FY2024 guidance for adjusted earnings before interest, tax, depreciation and amortisation to between €15m and €35m.
Revenues are expected to be between €790m and €820m, while R&D expenditure is expected to be €50m to €60m.
"The primary drivers of lower revenue and adjusted EBITDA guidance are related to the slower than anticipated conversion of sales orders into revenues and continued pressure on margins due to a still high fixed cost base," it said.
"However, the priority reset is fully on track and actions are underway to transform the business towards sustainable profitable growth."
At 1230 BST, the shares were down 35% at €5.39.
Compare our accounts
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
